Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses non-oral hormonal contraceptives and other exogenous steroid hormones, reporting they are generally safe for temporary use in women without breast cancer, but data are limited.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This review discusses hormone replacement therapy for menopausal women, emphasizing DHEA's unique ability to convert into sex steroids only in targeted tissues, and reports no new clinical results.

This study found that pregnane derivatives with higher lipophilicity, like compound 9d, had stronger androgen receptor binding and greater antiandrogenic effects in rats, correlating relative binding affinity with log P values.

This study found that chronic treatment with EE/LNG in female rats decreased brain concentrations of allopregnanolone, leading to reduced social and sexual behaviors; progesterone administration reversed these effects, except when finasteride was used to block the increase.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This article reviews the potential neuroprotective effects of 17α‐estradiol in neurodegenerative diseases and highlights its possibly lower toxicity compared to more feminizing hormones, but it reports no new clinical findings.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This article discusses the impact of estrogens on skin aging, highlighting the potential benefits and unresolved effectiveness of alternatives like phytoestrogens and selective estrogen receptor modulators; it reports no new clinical results.

This review discusses the use of ethinylestradiol combined with antiandrogenic progestin for treating androgenisation symptoms and improving metabolic and menstrual health in women, but it does not provide new clinical data.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

Hormonal contraceptives and therapies regulate organ functions and treat various conditions.

This study found that compound 10 inhibited testosterone conversion to DHT in hamster flank organs and seminal vesicles, whereas compound 11's inhibitory effect varied with dose, linked to halogen electronegativity differences.

This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.

This study reported that while finasteride and progesterone significantly inhibited dihydrotestosterone synthesis in dermal papillae, estrogens were less effective.

This article discusses the positive effects of estrogens and progestagens on various general diseases, but reports no new clinical results; the mechanisms and treatment approaches are presented.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This study found that progesterone derivatives with chlorine or bromine substituents were effective in inhibiting 5α-reductase activity in human prostate and exhibited antiandrogenic effects in hamster flank organs.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.